1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Characteristics of hemangioblastomas and brain metastases on conventional MR imaging
Tumor Solid-Cystic Solid Presence/Absence of SV Contrast-Enhancement Pattern
Homogeneous Heterogeneous
Hemangioblastomas 12/21 (57.1%) 9/21 (42.9%) 12/9 15/21 (71.5%) 6/21 (28.5%)
Brain metastases 6/30 (20%) 24/30 (80%) 6/24 5/30 (16.7%) 25/30 (83.3%)
Note:—SV indicates signal void.

Tumor	Solid-Cystic	Solid	Presence/Absence of SV	Contrast-Enhancement Pattern
Tumor	Solid-Cystic	Solid	Presence/Absence of SV	Homogeneous	Heterogeneous
Hemangioblastomas	12/21 (57.1%)	9/21 (42.9%)	12/9	15/21 (71.5%)	6/21 (28.5%)
Brain metastases	6/30 (20%)	24/30 (80%)	6/24	5/30 (16.7%)	25/30 (83.3%)